The Importance of Computerized Cognitive Assessment and Care Plan Development for Newly Diagnosed Patients

October 14, 2021Henry Peck

Computerized cognitive assessment and care plan development services are critical for newly diagnosed dementia patients to receive safe and proper care for the state of their cognitive, mental, and physical health. As an initial tool, these services can develop a baseline for care and can help determine the proper living situations for dementia patients, whether that be with in-home caregivers or in assisted living facilities. The required level of caregiver involvement can also be determined through such tools.

More often than not, these services are utilized sporadically, largely due to the lack of cognitive assessment tools available for longitudinal assessment of neurocognitive health. Furthermore, most tools only assess either cognition or function, making the practicality of longitudinal assessments of neurocognitive health challenging. As the cognitive and functional abilities of diagnosed patients change over time, the ability to complete Activities of Daily Living (ADLs) will also change, potentially resulting in new care needs. To effectively update care plans with changing needs, the ability of patients to complete complex ADLs should be regularly assessed and tracked over time.

Below, we explore commonly recommended measures to be taken for assessing several domains of care planning, the benefits of computerized cognitive assessments for care plan development, and how new neurocognitive assessment tools can improve patient care.

Domains of Care Planning

According to the Alzheimer’s Association, there are nine domains of care planning that should be assessed to determine care plans for dementia patients. Two of the most influential care planning domains include cognition and function. Let’s take a look into common tools used to assess these two critical domains.

Cognition

The most common and widely recognized tools are the Mini-Mental State Exam (MMSE), the Montreal Cognitive Assessment (MoCA), the Mini-Cog, and the General Practitioner Assessment of Cognition (GPCOG). The Alzheimer’s Association recommends the use of the Mini-Cog, the GPCOG, and the short MoCA. All of the assessments aim to assess the presence of cognitive impairment and incorporate similar aspects, such as memory, visuospatial functioning (Clock Drawing Test), language, orientation, attention, and calculation.

These assessments are good indicators of overall cognitive function. However, they pose several challenges and limitations. From a feasibility perspective, these assessments require a caregiver or healthcare professional to administer, interpret, and report on the results, making regular assessments of cognitive function challenging while also introducing the risk of bias or human-to-human variability. However, this issue may be addressed with computerized cognitive assessment and care plan development. 

These surface-level assessments rely on specific, symptom-oriented testing that may not provide the level of data granularity and specificity needed to fully understand a patient’s cognitive function to provide proper personalized care.

Function

To assess a patient’s functional abilities, the Alzheimer’s Association recommends the use of the Katz ADL and Lawton-Brody Instrumental ADL (IADL). Both assessments aim to assess a patient’s ability to perform ADLs or tasks necessary to live independently in a community. The respective categories for the assessment of functional abilities are detailed below.

Assessment Name

Categories for Assessment

Katz ADL

  • Bathing
  • Dressing
  • Toileting
  • Transferring
  • Continence
  • Feeding

Lawton-Brody IADL

  • Ability to Use Telephone
  • Shopping
  • Food Preparation
  • Housekeeping
  • Laundry
  • Mode of Transportation
  • Responsibility for Own Medications
  • Ability to Handle Finances

While both assessments may not be sensitive to small, incremental, intra-individual changes, the Lawton-Brody IADL is considered to assess ADLs of higher complexity compared to the Katz ADL. However, assessing a patient's ability to complete the eight types of activities through a demonstration of each task is very time-consuming and may lead to self-reporting or surrogate reporting methods. This can yield significant inaccuracies such as the overestimation or underestimation of functional abilities. 

Benefits of Computerized Cognitive Assessments for Care Plan Development

More recently, some caregivers and healthcare professionals have turned to computerized cognitive assessments for care plan development and, in some cases, computerized functional assessments. In general, computerized assessments have several advantages, including the following:

  • Digital tools are often easier to deploy and don’t rely on caregivers to administer.
  • Digital tools may provide better data quality from digital technologies.
  • Digital tools can be more user-friendly.

While computerized versions of existing tools eliminate several of the challenges associated with the assessments detailed above, they still have similar limitations regarding the data granularity and specificity required to provide a comprehensive understanding of a patient’s cognitive and functional abilities to provide personalized patient care.

Providing an Integrated Cognitive and Functional Assessment of ADLs

Altoida is developing a Precision Neurology platform and app-based medical device to measure and analyze nearly 800 cognitive and functional digital biomarkers from sensors in the user’s smartphone or tablet. By engaging in a 10-minute series of augmented reality and motor activities designed to simulate complex ADLs, Altoida transforms any smartphone or tablet into the world’s most powerful medical device to assess neurocognitive function.

To learn more about how Altoida’s precision neurology device can be used as a computerized neurocognitive assessment for care plan development, contact us today.

Contact Us

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
Contact Us

Contact Us

80 M Street SE, Suite 100 Washington, DC 20003 USA 

CONTACT@ALTOIDA.COM

Follow Us

Policy

By visiting our Website and/or using the Services in any manner, you acknowledge that you accept the practices and policies outlined in our Privacy Policy.
@ Altoida 2021
chevron-down